Issue 116 • March  2022

Uneven supply patterns hinder US rollout of Covid-19 antivirals

How AI could unlock the medical potential of psychedelics  

Is price control by stealth the future for the United States?

In association with

Cutting the carbon footprint of pharma’s supply chain

The pharmaceutical industry must reduce the carbon emissions associated with getting drugs to patients – but how?

In association with

02/23/2024 21:06:34
  • Home | Cutting the carbon footprint of pharma’s supply chain
  • In this issue
  • Contents
  • CSafe Global
  • Mimotopes Company Insight
  • Mimotopes
  • Briefing
  • Industry news
  • The pharma industry briefing
  • Covid-19 executive briefing by GlobalData
  • HOF Sonderanlagenbau
  • Comment
  • Is price control by stealth the future for the United States?
  • FDA approves Janus kinase inhibitors Rinvoq and Cibinqo despite safety concerns
  • Psychedelics: the next trip for CMOs
  • Over $1bn raised in venture capital funding for gene editing in 2021
  • Skyepharma
  • In Depth
  • How AI could unlock the medical potential of psychedelics
  • Covid-19 vaccine mixing: could heterologous boosters improve immunity?
  • Uneven supply patterns hinder US rollout of Covid-19 antivirals
  • Cutting the carbon footprint of pharma’s supply chain
  • Molnupiravir supplies dominate in times of Paxlovid scarcity
  • Wek-tec
  • In Data
  • Revealed: pharma leaders in precision, personalised medicine
  • Asia-Pacific is seeing a hiring boom in pharmaceutical cybersecurity roles
  • Venture financing deals in pharma rise in H2 2021
  • Global markets and indices
  • Macro-economic indicators
  • Macro-economic indicators (page 2)
  • Controlant Company Insight
  • Controlant
  • Event: Clinical Trial Supply New England 2022
  • Events
  • Next issue
02/16/2022 00:00:00